Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression
Ninghua Yao,Dengfu Yao,Li Wang,Zhizhen Dong,Wei Wu,Liwei Qiu,Xiaodi Yan,Dandan Yu,Jie Chen,Wenli Sai,Haijian Zhang,Junlin Yang
DOI: https://doi.org/10.1007/s13277-012-0436-x
2012-01-01
Tumor Biology
Abstract:Abnormal expression of insulin-like growth factor II (IGF-II) is associated with the hepatocyte malignant transformation and hepatocellular carcinoma (HCC) progress. In this study, specific IGF-II miRNA plasmids were constructed and transfected to HepG2 cells to knockdown IGF-II expression for observing effects on the cell proliferation, survival, apoptosis, angiogenesis, and anchorage-independent colony formation. IGF-II mRNA was evaluated by quantitative real-time polymerase chain reaction, and the level of IGF-II or vascular endothelial growth factor (VEGF) was quantitatively analyzed by ELISA. Our data shown that downregulation of IGF-II expression resulted in the viability alteration, proliferation inhibition, and apoptosis occurrence of HepG2 cells. The level of VEGF expression in the supernatant of HepG2 cells in the IGF-II-miRNA-transfected group was significantly decreasing ( P < 0.01) than those in the untransfected group or the miRNA-neg-transfected group, with the susceptibility to anoikis and decreasing of anchorage-independent colony formation of HepG2 cells. Thus, we conclude that IGF-II is a potential molecular target for HCC gene therapy.